Ra Pharmaceuticals (NASDAQ:RARX) Cut to Sell at BidaskClub

Ra Pharmaceuticals (NASDAQ:RARX) was downgraded by stock analysts at BidaskClub from a “hold” rating to a “sell” rating in a report released on Tuesday, BidAskClub reports.

Several other research analysts have also weighed in on RARX. Zacks Investment Research raised Ra Pharmaceuticals from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a research report on Tuesday. Leerink Swann began coverage on Ra Pharmaceuticals in a research report on Wednesday, May 22nd. They issued an “outperform” rating and a $23.30 price objective for the company. Svb Leerink began coverage on Ra Pharmaceuticals in a research report on Wednesday, May 22nd. They issued an “outperform” rating and a $33.00 price objective for the company. Raymond James set a $49.00 price objective on Ra Pharmaceuticals and gave the stock a “buy” rating in a research report on Wednesday, April 10th. Finally, BMO Capital Markets set a $33.00 price objective on Ra Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, March 8th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have issued a buy rating to the company’s stock. Ra Pharmaceuticals presently has an average rating of “Buy” and an average target price of $37.23.

Shares of NASDAQ:RARX opened at $20.87 on Tuesday. The firm has a market cap of $846.06 million, a P/E ratio of -10.13 and a beta of 0.79. The company has a debt-to-equity ratio of 0.02, a current ratio of 20.10 and a quick ratio of 20.10. Ra Pharmaceuticals has a 12-month low of $8.02 and a 12-month high of $27.68.

Ra Pharmaceuticals (NASDAQ:RARX) last posted its quarterly earnings data on Thursday, May 9th. The company reported ($0.45) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.47) by $0.02. Analysts expect that Ra Pharmaceuticals will post -1.98 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently modified their holdings of RARX. Bank of New York Mellon Corp grew its stake in shares of Ra Pharmaceuticals by 12.1% in the 3rd quarter. Bank of New York Mellon Corp now owns 53,759 shares of the company’s stock valued at $973,000 after buying an additional 5,797 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Ra Pharmaceuticals by 19.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 313,700 shares of the company’s stock valued at $5,674,000 after buying an additional 51,010 shares during the period. Vanguard Group Inc. grew its stake in shares of Ra Pharmaceuticals by 9.1% in the 3rd quarter. Vanguard Group Inc. now owns 739,337 shares of the company’s stock valued at $13,374,000 after buying an additional 61,929 shares during the period. Quantamental Technologies LLC acquired a new stake in shares of Ra Pharmaceuticals in the 4th quarter valued at about $44,000. Finally, Rhumbline Advisers grew its stake in shares of Ra Pharmaceuticals by 45.0% in the 4th quarter. Rhumbline Advisers now owns 20,725 shares of the company’s stock valued at $377,000 after buying an additional 6,432 shares during the period. Institutional investors own 94.97% of the company’s stock.

Ra Pharmaceuticals Company Profile

Ra Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules.

Featured Article: Diversification in Your Portfolio

Analyst Recommendations for Ra Pharmaceuticals (NASDAQ:RARX)

Receive News & Ratings for Ra Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ra Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.